J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining…
Latest News
-
-
JPM26: 2025 a “breakout year” for rare disease biotechs
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies…
-
JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
Amgen’s obesity and type 2 diabetes (T2D) hopeful, MariTide (maridebart cafraglutide), has demonstrated its once-quarterly dosing potential in a mid-stage…
-
JPM26: HIV pipeline dosing optionality gives Gilead advantage
Gilead’s range of treatments and prevention for human immunodeficiency virus (HIV), both on the market and in the pipeline, provides…
-
GSK to file for approval of hep B drug on positive Phase III data
GSK’s triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis B…
-
Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs
Eli Lilly’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA), orforglipron, has proven its efficacy as a maintenance therapy in patients…
-
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
Pfizer has confirmed another push into the obesity market in the form of a licencing deal worth up to approximately…
-
FDA steps back from preclinical primate testing amid wider regulatory shift
The US Food and Drug Administration (FDA) has taken another step away from animal testing – this time through draft…
-
GLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide miss
Novo Nordisk’s Rybelsus (oral semaglutide) has failed to demonstrate efficacy in a late-stage trial in Alzheimer’s disease, denting hopes of…
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by…
